ClinicalTrials.gg
RecruitingNCT05719701Updated Apr 9, 2024

Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma

A Phase 1/2 interventional study of ICP-490 and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Recruiting at 6 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-09.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started Mar 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 448 studies in Multiple Myeloma with a site in China — 238 open to participants now, 275 under way, 47 of them phase 3. Multiple Myeloma · China.

Planned enrollment
131st of 406
80 · median 40
Started
2023
with 59 others
Phase 1/2
65 of 448
43 open now
Primary completion
2025-07
later than 43 of 274 live
Registered
226th of 448
by date

Among the 448 studies in Multiple Myeloma with a site in China, this one is the 131st largest by planned enrollment of the 406 interventional ones that give a count, is one of 60 that started in 2023, is one of 65 in phase 1/2, reaches primary completion later than 43 of the 274 other live ones, and was the 226th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

238 of the 448 studies in Multiple Myeloma with a site in China are open now. Recruiting first, the newest first:

233 more — sign in →

All 238 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 584 Multiple Myeloma studies recruiting now, 429 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 448 studies in Multiple Myeloma with a site in China, or all of them as a file.
02

Study summary

This is a multi-center, non-randomized and open-label phase I/IIa clinical study to evaluate the safety, tolerability, and efficacy of ICP-490 in patients with relapsed and/or refractory multiple myeloma.

03

Conditions studied

  • Relapsed and/or Refractory Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥ 18 years old.
  2. Diagnosed as multiple myeloma .The patient must have measurable diseases. (ECOG) Performance Status (PS) score of 0-2.
  3. Patients must have adequate organ function. Expected survival time ≥ 6 months.
  4. All toxicities caused by prior anticancer therapy must have recovered to Grade ≤ 1 (based on v5.0) except alopecia and fatigue.

Female patients of should have a negative blood pregnancy test result within 48 h prior to the first dose of drug.

Exclusion criteria

Exclusion Criteria:

  1. Known active central nervous system (CNS) involvement or history of the disease, or clinical signs of multiple myeloma meningeal/spinal meningeal involvement.
  2. Patients with solitary plasmacytoma; plasma cell leukemia (PCL) (active PCL or history of PCL); Waldenström's macroglobulinemia; POEMS syndrome or symptomatic amyloidosis.
  3. Prior active or history of other than MM, occurring within 5 years prior to the first dose of drug, with the exception of radically treated local curable cancers.
  4. Uncontrolled or severe cardiovascular disorders.
  5. Any active infection within 14 days prior to the first dose of investigational drug.
  6. Patients with diseases restricted from participation as described in the protocol
  7. Having undergone major surgery within 28 days prior to the first dose of investigational drug, or minor surgery within 2 weeks prior to the first dose. Any severe or uncontrolled systemic disease evaluated by investigatorthat may increase the risk associated with study participation and drug administration or affect the patient's ability to receive the investigational drug.
  8. Patients who have received any other systemic treatment, anti-tumor traditional Chinese (herbal) medicine therapy , and any other investigational drug therapy for MM within 28 days or 5 half-lives of the drugs (whichever is shorter) prior to the first dose of investigational drug.
  9. Patients who have received systemic treatment with or other drugs within 14 days prior to the first dose of investigational drug.

    Subjects are allowed to use topical, ocular, intra-articular, intranasal, and inhaledcorticosteroid ; short-term use (≤ 7 days) of corticosteroid for prophylaxis (e.g., contrast agent allergy) or for the treatment of non- diseases (e.g., delayed reaction caused by contact allergens) is permitted.

  10. Patients who have received medications or foods with strong inhibitory or inductive effects on cytochrome P450 , and proton pump inhibitorswithin 2 weeks prior to the first dose of investigational drug, or are planning to receive them during the study.
  11. Patients with a history of severe allergic reactions to IMIDs , or dexamethasone, or to any component contained in ICP-490 or dexamethasone formulation ( V5.0 Grade > 3).
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    ICP-490

    Drug: ICP-490

  • Experimental
    ICP-490 in combination with Dexamethasone

    Drug: ICP-490 · Drug: Dexamethasone

Interventions

  • DrugICP-490

    Several dose groups of ICP-490 are planned for the dose exploration.

  • Oral Dexamethasone is administered on Days 1, 8, 15, and 22 of each 28-day cycle.

06

What researchers measure

Primary outcomes

  1. Phase I : Incidence, type, and severity of adverse events (AEs) as judged according to NCI-CTCAE V5.0

    AE refers to any adverse event occurring in subjects during clinical research period. The incidence and type of AEs will be evaluated and the severity will be judged according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version5.0.

    Time frame: Through study completion, an average of 3 years

  2. Phase I : Incidence, type, and severity of dose-limiting toxicities (DLTs)

    The dose-limiting toxicity (DLT) assessed in the phase I dose exploration study is defined as AEs related to study treatment that meet the following criteria (according to the NCI CTCAE v5.0 criteria) and occur in Cycle 1.

    Time frame: Through study completion, an average of 3 years

  3. Phase I : RP2Ds and/or MTDs

    Phase I is the dose exploration study of ICP-490 to preliminarily determine RP2Ds (probably more than one) and MTD (if applicable). MTD: The dose level corresponding to the dose group whose posterior probability of DLT incidence estimated by PAVA (pool adjacent violators algorithm) is closest to the target toxicity probability (25%).

    Time frame: Through study completion, an average of 3 years

  4. Phase II : ORR (defined as sCR + CR + VGPR + PR) assessed according to IMWG criteria.

    Disease response will be assessed according to the 2016 IMWG response criteria.

    Time frame: Through study completion, an average of 3 years

Secondary outcomes

  1. Maximum concentration (Cmax)

    Maximum concentration (Cmax) will be calculated through multiple plasma concentrations drawn from the patients after administration.

    Time frame: Through study completion, an average of 3 years

  2. Time to maximum concentration (Tmax)

    Time to maximum concentration (Tmax) will be calculated through multiple plasma concentrations drawn from the patients after administration.

    Time frame: Through study completion, an average of 3 years

  3. Half-life (T1/2)

    Half-life (T1/2) will be calculated through multiple plasma concentrations drawn from the patients after administration.

    Time frame: Through study completion, an average of 3 years

  4. Area under the concentration-time curve (AUC0-∞ and AUC0-t)

    Area under the concentration-time curve (AUC0-∞ and AUC0-t) will be calculated through multiple plasma concentrations drawn from the patients after administration.

    Time frame: Through study completion, an average of 3 years

  5. Apparent clearance (CL/F)

    Apparent clearance (CL/F) will be calculated through multiple plasma concentrations drawn from the patients after administration.

    Time frame: Through study completion, an average of 3 years

  6. Apparent volume of distribution during terminal phase (Vz/F)

    Apparent volume of distribution during terminal phase (Vz/F) will be calculated through multiple plasma concentrations drawn from the patients after administration.

    Time frame: Through study completion, an average of 3 years

  7. Steady-state PK parameters

    Steady-state PK parameters will be calculated through multiple plasma concentrations drawn from the patients after administration.

    Time frame: Through study completion, an average of 3 years

  8. The overall response rate (ORR) assessed according to the International Myeloma Working Group (IMWG) criteria (ORR, defined as stringent complete response (sCR) + complete response (CR) + very good partial response (VGPR) + partial response (PR))

    Disease response will be assessed according to the 2016 IMWG response criteria.

    Time frame: Through study completion, an average of 3 years

  9. Phase I & IIa : Complete response rate (CRR, defined as sCR + CR) assessed according to IMWG criteria

    Disease response will be assessed according to the 2016 IMWG response criteria.

    Time frame: Through study completion, an average of 3 years

  10. Phase I & IIa : Very good or better partial response rate assessed according to IMWG criteria (≥ VGPR rate, defined as VGPR + sCR + CR)

    Disease response will be assessed according to the 2016 IMWG response criteria.

    Time frame: Through study completion, an average of 3 years

  11. Phase I & IIa : Time to response (TTR) assessed according to IMWG criteria

    Disease response will be assessed according to the 2016 IMWG response criteria

    Time frame: Through study completion, an average of 3 years

  12. Phase I & IIa : Duration of response (DOR) assessed according to IMWG criteria

    Disease response will be assessed according to the 2016 IMWG response criteria

    Time frame: Through study completion, an average of 3 years

  13. Phase I & IIa : Progression-free survival (PFS) assessed according to IMWG criteria

    Disease response will be assessed according to the 2016 IMWG response criteria

    Time frame: Through study completion, an average of 3 years

  14. Phase I & IIa : Overall survival (OS)

    The follow-up visits should be carried out every 12 weeks after the last dose via telephone or other methods to obtain the survival status information of patients.

    Time frame: Through study completion, an average of 3 years

07

Study locations

1 of 6 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Jul 2025, 28 months after the start.

Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's planned 28 months is below that.

Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2023
First posted
Feb 9, 2023
StartActual
Mar 29, 2023
Primary completionEst.
Jul 30, 2025
CompletionEst.
Dec 30, 2025
Last update
Apr 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05719701
Responsible party
Sponsor
First posted
Feb 9, 2023
Start date
Mar 29, 2023
Primary completion
Jul 30, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Apr 9, 2024

Study contacts

April Huang
Contact
April.huang@innocarepharma.com
010-66609723

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion